Revolution Medicines, Inc.
RVMD
NASDAQ·Healthcare·Biotechnology·Mkt cap $44.6B
$210.02
▼ -0.40%
P/E
-23.70
Mkt Cap
$44.6B
52-Wk Range
$39.73–$224.31
52-Week Range
$39.73 - $224.31
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 411.5% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Proprietary RAS pathway inhibition platform targeting multiple frontier oncology targets
- Strategic partnership with Sanofi providing development expertise and commercialization support
- Differentiated pipeline with mutant-selective and hyperactivated inhibitor approaches
- Focus on RAS-addicted cancers with limited current treatment options
- Clinical-stage validation with multiple candidates in active development
Bear Case
1 risk
- Average volatility.
Growth
Stable outlook
Advancement of RMC-4630 through Phase 1/2 trials with potential for expanded indications
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+41.4% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying RVMD right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 4, 2026
AUG 5, 2026
Reported EPS of -$3.06 vs -$2.04 consensus (-50.0% surprise).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-50.0%
Revenue trend · last 8Q
—
-100%
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
17 analysts · 94% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
94%
Hold
6%
Sell
0%
Median Price Target
$235.00
▲ +11.9% vs $210.02
Latest: Needham · Aug 31, 2026
1 analyst covering
vs Industry
How RVMD stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related